COGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cogent Biosciences Inc (COGT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive long-term potential based on analyst ratings and clinical trial results, the current technical indicators, insider selling trends, and lack of immediate catalysts suggest that waiting for a better entry point may be more prudent.
The MACD is negatively expanding (-0.115), RSI is neutral (43.181), and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level (37.016) with support at 35.868, suggesting potential downside risk in the short term.
Hedge funds have significantly increased their buying activity (+2828.69% last quarter). Analysts have raised price targets, citing strong clinical trial results and a potential $7B market opportunity for its lead drug candidate. The stock has a 7.76% chance of increasing in the next month based on historical patterns.
Insiders have increased selling activity by 946.09% in the last month, which could signal a lack of confidence in near-term performance. Technical indicators do not show a strong upward trend, and the stock price has declined by 1.29% in the regular market session.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$80.93M, which improved by 14.58% YoY. However, EPS dropped by -7.81% YoY to -0.59, indicating ongoing financial challenges.
Analysts are bullish on the stock, with multiple price target increases: H.C. Wainwright ($52), JPMorgan ($67), and Jefferies ($48). The consensus highlights strong clinical trial results and a differentiated drug profile, positioning the company for long-term growth.
